The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.

Tag:

Pfizer

Latest Headlines

Latest Headlines

Groton throws up a new hurdle to Pfizer's R&D demolition plan

It looks as if Pfizer is going to have to submit to some counseling from a group of anxious economic development officials in Connecticut before the pharma giant will be allowed to reduce a sprawling R&D facility to rubble.

Pfizer needs consumer unit as pipeline in prescription to OTC trend

Pfizer CEO Ian Read has given yet another glimpse into the future of the drugmaker as he shapes it into a more efficient pharmaceutical operation. In a disappointing disclosure to those who look for more spinoffs, he said Pfizer will hold onto its consumer health business.

Odors lead to back order for Pfizer's Levoxyl

Drugs being pulled off of shelves because of bad odors generally have no health risks associated with them, but they cost drugmakers money and consumers inconvenience.

Pfizer fails to block $142M Neurontin award, faces 2 more suits

Pfizer's potential liability on off-label Neurontin use just grew: A U.S. appeals court in Boston upheld a $142 million verdict in one lawsuit and reinstated two others that had been tossed out by lower courts--including a class action that could allow hundreds of health plans to pursue claims against the company

Text message campaign fails to boost vaccination rate

A pilot study has brought dispiriting news for proponents of boosting vaccine adherence through text messaging. A study found that a series of text message prompts failed to increase vaccination rates among pregnant women.

J&J, Pfizer chip in on $18M round for anti-inflammatory biotech's PhII

The venture arms for Johnson & Johnson and Pfizer have helped spearhead an $18 million investment round for Canada's Aquinox Pharmaceuticals as the biotech plots the next big step in a mid-stage program for its lead anti-inflammatory drug.

Pfizer, Novartis eye bids for Brazil's Ache in deal worth $5B

Some Big Pharma heavyweights are duking it out for Brazil's Aché Laboratorios Farmaceuticos.  Reuters  sources say Pfizer, Novartis and Abbott Laboratories are in the fight, sizing up second-round bids in a deal worth around $5 billion.

Resurgent Pfizer partners with Bind on new nanotech drug effort

Just a few months after inking a tie-up with Amgen, Bind Therapeutics has come back from the deal table with another marquee partner looking to use its nanoengineering platform to launch newly amped-up treatments into the clinic.

Pfizer's demolition plans in Groton stymie local officials

Now that Pfizer ( $PFE ) has wrapped up its big round of layoffs in Groton, CT, the company is bringing in the wrecking ball. And its plan to raze Building 118, Pfizer's sprawling...

Connecticut pols stunned as Pfizer brings in the wrecking ball

Now that Pfizer has completed its big round of layoffs at Groton, CT, the pharma giant has decided to bring in the wrecking ball for Building 118, its sprawling 750,000-square-foot research facility on the campus.